Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncology. 2009;77(1):49-52. doi: 10.1159/000226111. Epub 2009 Jun 25.

Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.

Author information

1
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. kakeji@surg2.med.kyushu-u.ac.jp

Abstract

OBJECTIVE:

This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer.

METHODS:

Patients with measurable advanced or recurrent gastric cancer and no prior exposure to the investigational drugs were treated with intravenous docetaxel 35 mg/m(2) on days 1 and 15, and oral S-1 80 mg/m(2)/day on days 1-14 every 4 weeks. The primary endpoint was objective response.

RESULTS:

Thirty-five eligible patients were enrolled and received a total of 151 cycles of treatment (median 3, range 1-19). One complete response and 13 partial responses were observed, with an overall response rate of 40% (95% CI: 24-56%). Median progression-free survival and median overall survival times were 4.5 and 14.2 months, respectively. The most common grade 3-4 toxicities were neutropenia (23%) and leukocytopenia (15%).

CONCLUSION:

Biweekly docetaxel combined with S-1 is active in advanced or recurrent gastric cancer, and can be administered with proper management of adverse events in an outpatient clinic.

PMID:
19556809
DOI:
10.1159/000226111
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Support Center